Recent studies examine the burden of CRSwNP, looking at quality of life in patients and caregivers and assessing how CRSwNP ...

Hopeful the drug will be approved for treating nasal polyps, he said: “All being well, if the price is right, Nice and SMC ...

Patients with chronic rhinosinusitis with nasal polyps saw improvements across all endpoints with tezepelumab, according to ...

The total nasal-polyp score was the sum of the right and left nostril scores, with the score for each nostril ranging from 0 (no nasal polyps) to 4 (large nasal polyps causing complete or near ...

Trial results in nasal polyps reported late last year showed ... with the CRSwNP indication worth up to $1 billion in in its own right. That will depend on how well it is received by payers ...

In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic ...

Opens in a new tab or window SAN DIEGO -- Novel ultra-long-acting biologic depemokimab reduced nasal polyps in chronic rhinosinusitis, two parallel phase III trials showed. Twice-yearly injections ...

SAN DIEGO — Among patients with previous sinus surgery for chronic rhinosinusitis with nasal polyps, the number of past surgeries did not alter the benefits of mepolizumab on nasal polyp and VAS ...

Tezepelumab reduced the size of nasal polyps and the severity of nasal congestion in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps, in a placebo-controlled study.